PAN endonuclease-IN-2 (compound T-31) is a PAN endonuclease inhibitor (IC50: 0.15 μM) and antiviral agent with broad-spectrum anti- Influenza activity. PAN is the N-terminal PA subunit of the polymerase-RNA complex and the dependent endonuclease (CEN) active site. PAN initiates RNA replication by promoting cleavage of the RNA strand and allowing the polymerase to begin synthesizing […]

pan-HCN-IN-1 (Compound J&J12e) is an inhibitor for hyperpolarization-activated and cyclic-nucleotide-gated 1 (HCN1) ion channel, with IC50 of 58 nM. pan-HCN-IN-1 reduces the voltage sag response and enhances EPSP summation in ex vivo rats brain slices[1].

pan-KRAS-IN-10 (Compound 58) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.7 and 0.24 nM, respectively[1].

pan-KRAS-IN-13 (compound 2) is a potent inhibitor of KRAS, with IC50s of 2.75 nM and 2.89 nM for G12D and G12V, respectively[1]

pan-KRAS-IN-14 (compound 20) is a Pan-KRAS inhibitor (IC50 =2.3 nM)[1].

pan-KRAS-IN-5 (compound 15a) is a pan-KRAS translation inhibitor by targeting 5′-UTR RNA G-quadruplexes (rG4s). pan-KRAS-IN-5 induces cell cycle arrest and promptes apoptosis in KRAS-driven cancer cells[1].

pan-KRAS-IN-7 (Compound 25) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.35 and 0.51 nM, respectively[1].

pan-KRAS-IN-8 (Compound 38) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.07 and 0.18 nM, respectively[1].

pan-KRAS-IN-9 (Compound 52) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.24 and 0.30 nM, respectively[1].

PAN2 Human Pre-designed siRNA Set A contains three designed siRNAs for PAN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAN3 Human Pre-designed siRNA Set A contains three designed siRNAs for PAN3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pancuronium (dibromide) (Standard) is the analytical standard of Pancuronium (dibromide). This product is intended for research and analytical applications. Pancuronium dibromide, a bis-quaternary steroid, is a neuromuscular relaxant. Pancuronium dibromide inhibits neuromuscular transmission by competing with acetylcholine for binding sites on nACh receptors. Pancuronium dibromide also inhibits cardiac muscarinic receptors and has a sympathomimetic action[1][2][3].

PANK1 Human Pre-designed siRNA Set A contains three designed siRNAs for PANK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PANK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PANK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PANK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PANK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PANK4 Human Pre-designed siRNA Set A contains three designed siRNAs for PANK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PANO1 Human Pre-designed siRNA Set A contains three designed siRNAs for PANO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pantethine-15N2 is the 15N2 labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer’s disease, Parkinson’s disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration[1][2][3][4][5][6].

Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole sodium, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and […]

PANX1 Human Pre-designed siRNA Set A contains three designed siRNAs for PANX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PANX2 Human Pre-designed siRNA Set A contains three designed siRNAs for PANX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PANX3 Human Pre-designed siRNA Set A contains three designed siRNAs for PANX3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAOX Human Pre-designed siRNA Set A contains three designed siRNAs for PAOX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAPLN Human Pre-designed siRNA Set A contains three designed siRNAs for PAPLN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAPOLA Human Pre-designed siRNA Set A contains three designed siRNAs for PAPOLA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAPOLG Human Pre-designed siRNA Set A contains three designed siRNAs for PAPOLG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAPPA Human Pre-designed siRNA Set A contains three designed siRNAs for PAPPA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAPPA2 Human Pre-designed siRNA Set A contains three designed siRNAs for PAPPA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAPSS1 Human Pre-designed siRNA Set A contains three designed siRNAs for PAPSS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAPSS2 Human Pre-designed siRNA Set A contains three designed siRNAs for PAPSS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells[1].

PAQR4 Human Pre-designed siRNA Set A contains three designed siRNAs for PAQR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAQR5 Human Pre-designed siRNA Set A contains three designed siRNAs for PAQR5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAQR7 Human Pre-designed siRNA Set A contains three designed siRNAs for PAQR7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAQR8 Human Pre-designed siRNA Set A contains three designed siRNAs for PAQR8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAQR9 Human Pre-designed siRNA Set A contains three designed siRNAs for PAQR9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PAR 4 (1-6) human, a hexapeptide, is a fragment of protease-activated receptor 4 (PAR4). PAR 4 (1-6) TFA acts as a PAR4-specific agonist[1].

PAR4 antagonist 1 (Compound 48) is a protease activated receptor 4 (PAR4) antagonist with an IC50 of 1.8 nM. PAR4 antagonist 1 has an IC50 of 2 nM against γ-thrombin-activated PAR4 in platelet-rich plasma (PRP). PAR4 antagonist 1 can be used in antithrombotic research[1].

PAR4 antagonist 2 (Compound 31) is a protease activated receptor 4 (PAR4) antagonist, with IC50 values of 95 nM and 367 nM for human PAR4 and mouse PAR4. PAR4 antagonist 2 is active against PAR4 activation by the native protease thrombin cleavage but not the synthetic PAR4 agonist peptide AYPGKF[1].

PAR4 antagonist 3 (Compound 36) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC50 of 26.1 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T1/2 of 97.6 min[1].

PAR4 antagonist 4 (Compound 37) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC50 of 14.2 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T1/2 of 42.5 min[1].

PAR4 antagonist 5 (compound 1) is a PAR4 antagonist with an IC50 less than 20 μM and potent anti-platelet aggregation activity. PAR4 antagonist 5 can be used for research of thrombosis disease [1].

Paracetamol-cysteine (TFA) is an acetaminophen-protein adduct formed during the metabolism of acetaminophen (HY-66005)[1].

Paracetamol-cysteine (TFA) is an acetaminophen-protein adduct formed during the metabolism of acetaminophen (HY-66005)[1].